What to monitor while on statins?
The ATP III recommendations for monitoring of statin therapy are as follows: check lipid panel at baseline, 6–8 weeks after starting or adjusting the medication/dose, and then every 4–6 months; check LFTs at baseline, approximately 12 weeks after starting therapy, then annually or more frequently if indicated; and …
Which statin is best for elevated liver enzymes?
These findings favor the safe use of pravastatin in patients with well-compensated chronic liver disease and hypercholesterolemia.
When should you recheck liver function after starting statins?
LFTs should be checked 6 to 8 weeks after commencing treatment or any dosage increase. A yearly check of LFTs is not required for patients who are stable on long-term treatment. If ALT <150: continue statin but recheck LFTs within 4 weeks to exclude further increase in ALT.
How often should you check LFTs on statin?
– NICE suggest LFTs should be checked within 3 months and 12 months after commencing medication. Routine monitoring thereafter in patients on statins is not recommended unless clinically indicated or if the statin is given in combination with fibrate therapy.
Is liver damage from statins reversible?
Fortunately, severe liver injury is uncommon with statin use and is generally reversible without any intervention other than offending statin cessation.
Which statins are easiest on the liver?
Doctor’s response. Low dose statins like atorvastatin (Lipitor) are safe in patients with mild liver disease (for example, patients with fatty liver and mildly abnormal liver tests in the blood such as ALT and AST).
Which statin is easiest on liver?
Low dose statins like atorvastatin (Lipitor) are safe in patients with mild liver disease (for example, patients with fatty liver and mildly abnormal liver tests in the blood such as ALT and AST).
How do you measure statin intensity?
Intensity of statin therapy is defined based on the average LDL-C response to a specific statin dose. High-intensity statin therapy reduces ASCVD events more than moderate-intensity therapy, but lower-intensity statin therapy has also been shown to reduce ASCVD events, although to a lesser degree.